Proton therapy for uveal melanomas and other eye lesions

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL. 2, 1999, Pages 68-73

  Munzenrider, John E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Age related macular degeneration; And metastasis; Hemangiomas; Ocular angiomas; Proton therapy; Uveal melanoma

Indexed keywords

AGE; ANGIOMA; BEAM THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; EYE TUMOR; HEMANGIOMA; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; RETINA MACULA DEGENERATION; RETINOBLASTOMA; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR VOLUME; UVEA MELANOMA;

EID: 0032738016     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03038893     Document Type: Conference Paper

References (55)

1. Stallard HB. Malignant melanoblastoma of the choroid. Mod Prob Ophthalmol 1966;7:16-38.
2. Cruess AF, Augsburger JJ, Shields JA, et al. Visual results following Cobalt plaque radiotherapy for posterior uveal melanomas. Ophthalmol 1984;91:131-6.
3. Garretson BR, Robertson DM, Earle JK. Choroidal melanoma treatment with iodine-125 brachytherapy. Arch Ophthalmol 1987;105:1394-7.
4. Lommatzsch PK. Beta-irradiation of choroidal melanoma with 106Ru/ 106Rh applicators. Arch Ophthalmol 1983;101:713-7.
5. Marcoe AM, Brady LW, Shields J, et al. Radioactive eye plaque therapy versus enucleation for the treatment of posterior uveal malignant melanoma. Radiology 1985;156:801-3.
6. Rotman M, Long RS, Packer S, et al. Radiation therapy of uveal melanomas. Trans Ophthalmol Soc UK 1977;97:431-5.
7. Brovkina, AF, Zarubei GD. Ciliochoroidal melanomas treated with a narrow medical proton beam. Arch Ophthalmol 1986;104:402-4.
8. Char DH, Castro JR, Kroll SM, et al. Five-year follow-up of helium ion therapy for uveal melanoma. Ophthalmol 1990;108:209-14.
9. Bonnet DE, Kacperek A, Sheen MA, et al. The 62 MeV proton beam for the treatment of ocular melanoma at Clatterbridge. Br J Radiol 1993;66: 907-14.
10. Gragoudas ES, Seddon JM, Egan K, et al. Long-term results of proton beam irradiated uveal melanomas. Arch Ophthalmol 1987;94:349-53.
11. Zografos L, Perret C, Egger E, et al. Proton Beam Irradiation of Uveal Melanomas at Paul Scherrer Institute (former SIN). Strahlenther Onkol 1990;166:114.
12. Castro JR, Char DH, Petti PL, et al. 15 years experience with helium ion radiotherapy for uveal melanoma. Int J Radiation Oncology Biol Phys 1997;39:989-96.
13. Tsunemoto H, Morita S, Kawachi K, et al. Clinical results of proton radiotherapy in Japan. Proceedings of the 8th International Cong of Rad Research. Edinburgh, 1987, pp. 922-7.
14. Daftari IK, Char DH, Verhey LJ, et al. Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. Int J Radiation Oncology Biol Phys 1997;39:997-1010.
15. Slater JM, Archambeau JO, Miller DW, et al. The proton treatment center at Loma Linda University Medical Center: Rationale for and description of its development. Int J Radiat Oncol Biol Phys 1992:22:383-9.
16. Archambeau JO, Mao XW, Yonemoto LT, et al. What is the role of radiation in the treatment of subfoveal membranes: Review of radiobiologic, pathologic, and other considerations to initiate a multimodality discussion. Int J Radiat Oncol Biol Phys 1998;40:1125-36.
17. Castro JR, Petti PL, Blakely EA, et al. Particle Radiation Therapy. In: Leibel SA, Phillips TL (eds.). Textbook of Radiotherapy. New York: W B Saunders, 1998.
18. Constable IJ, Koehler AM, Schmidt RA. Proton irradiation of simulated ocular tumors. Investig Ophthalmol 1975;14:547-55.
19. Constable IJ, Goitein M, Koehler AM, et al. Small field irradiation of monkey eyes with protons and photons. Radiation Research 1976;65: 304-14.
20. Gragoudas ES, Zakov NZ, Albert DM, et al. Long term observations of proton-irradiated monkey eyes. Arch Ophthalmol 1979;97:2184-91.
21. The Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1. Ophthalmol 1990;108:1268-73.
22. Goitein M, Miller T. Planning proton therapy of the eye. Med Phys 1983; 10:275-83.
23. Gragoudas ES, Goitein M, Koehler AM, et al. Proton irradiation of small choroidal malignant melanomas. Am J Ophthalmol 1977;83:655-73.
24. Gragoudas ES, Goitein M, Verhey LJ, et al. Proton beam irradiation. An alternative to enucleation for intraocular melanoma. Ophthalmol 1980;87: 571-81.
25. Verhey LJ, Goitein M, Munzenrider JE, et al. Precise positioning of patients for radiation therapy. Int J Radiat Oncol Biol 1982;8:289-94.
26. Urano M, Goitein M, Verhey LJ, et al. Relative biological effectiveness of modulated proton beams in various murine tissues. Int J Radiat Oncol Biol Phys 1984;10:509-14.
27. Yashkin PN, Silin DI, Zolotov VA, et al. Relative biological effectiveness of proton medical beam at Moscow Synchotron determined by the Chinese Hamster Cells assay. Int J Radiat Oncol Biol Phys 1995;31:535-40.
28. Miller DW. A review of proton beam radiotherapy. Med Phys 1995;22: 1943-54.
29. Munzenrider JE, Verhey L, Gragoudas ES, et al. Conservative treatment of uveal melanoma: Dose distribution to tumors with local recurrence after proton beam therapy. Int J Radiation Oncology Biol Phys 1989;17: 493-8.
30. Gragoudas ES, Seddon JM, Polivogianis LL, et al. Prognostic factors for metastasis following proton beam irradiation of uveal melanomas. Ophthalmol 1986;93:675-80.
31. Gragoudas ES, Seddon JM, Egan KM, et al. Metastasis from uveal melanoma after proton beam irradiation. Ophthalmol 1988;95:992-9.
32. Seddon JM, Gragoudas ES, Albert DM, et al. Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am J Ophthalmol 1985;99:282-90.
33. Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmol 1990;97:769-77.
34. Seddon JM, Albert DM, Lavin P, et al. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983;101:1894-9.
35. Egan K, Gragoudas ES, Seddon JM, et al. The risk of enucleation after proton beam irradiation of uveal melanoma. Ophthalmol 1989;96:1377-83.
36. Ferry AP, Blair, CJ, Gragoudas ES, et al. Pathologic examination of ciliary body melanoma treated with proton beam irradiation. Arch Ophthalmol 1985;103:1849-53.
37. Kincaid MC, Folberg R, Torczynski E, et al. Complications after proton beam therapy for uveal malignant melanoma. Ophthalmol 1988;95:982-91.
38. Seddon JM, Gragoudas ES, Albert DM. Ciliary body and choroidal melanomas treated by proton beam irradiation: Histopathologic study of eyes. Arch Ophthalmol 1983;101:1402-8.
39. Zinn KM, Stein/Pokorny K, Jakobiec F, et al. Proton beam irradiated epithelial cell melanoma of the ciliary body. Ophthalmol 1981;88:1315-21.
40. Egan KM, Ryan LM, Gragoudas ES. Survival implications of enucleation after definitive radiotherapy for choroidal melanoma. An example of regression on time-dependent covariates. Arch Ophthalmol 1998;116:366-70.
41. Gragoudas ES, Egan KM, Arrigg PG, et al. Cataract extraction after proton beam irradiation for malignant melanoma of the eye. Arch Ophthalmol 1992;110:475-9.
42. Gragoudas ES, Egan KM, Walsh SM, et al. Lens changes after proton beam irradiation for uveal melanoma. Am J Ophthalmol 1995;119:157-64.
43. Seddon JM, Gragoudas ES, Polivogianis L, et al. Visual outcome after proton beam irradiation of uveal melanoma. Ophthalmol 1986;93:666-74.
44. Seddon JM, Gragoudas ES, Egan KM, et al. Uveal melanomas near the optic disc or fovea. Visual results after proton beam irradiation. Ophthalmol 1987;94:354-61.
45. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon Alpha-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
46. Char DH, Quivey JM, Castro JR, et al. Helium Ions versus Iodine-125 brachytherapy in the management of uveal melanoma, a prospective randomized dynamically balanced trial. Ophthalmology 1993;100:1547-54.
47. American Academy of Ophthalmology. Age-related macular degeneration and choroidal neovascularization. American Academy of Ophthalmology 1994 (monograph).
48. Smith LM, Donaldson SS, Egbert PR, et al. Aggressive management of second primary tumors in survivors of hereditary retinoblastoma. Int J Radiat Oncol Biol Phys 1989;17:499-505.
49. Wong FL, Boice JD, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. J Amer Med Soc 1998;278: 1262-7.
50. Kaste SC, Chen G, Fontanesi J, et al. Orbital development in long-term survivors of retinoblastoma. J Clin Oncol 1997;15:1183-9.
51. Goitein M, Abrams M. Multi-dimensional treatment planning: 1. Delineation of anatomy. Int J Radiat Oncol Biol Phys 1983;9:777-87.
52. Goitein M, Abrams M, Rowell D, et al. Multi-dimensional treatment planning: II. Beam's eye-view, back projection and projection through CT sections. Int J Radiat Oncol Biol. Phys 1983;9:789-97.
53. Urie M, Goitein M, Wagner M. Compensating for heterogeneities in proton radiation therapy. Phys Med Biol 1983;29:553-66.
54. Mukai S. Management of retinoblasloma. Sem in Ophthalmol 1993;8: 281-91.
55. Urie M, Goitein M. Variable versus fixed modulation of proton beams for treatment in the cranium. Med Phys 1989;16:593.